Read-Gene S.A. (WSE:RDG)

Poland flag Poland · Delayed Price · Currency is PLN
5.50
-0.32 (-5.50%)
Last updated: Feb 27, 2026, 12:45 PM CET
30.33%
Market Cap 64.85M
Revenue (ttm) 15.57M
Net Income (ttm) 808.33K
Shares Out 11.79M
EPS (ttm) 0.07
PE Ratio 80.22
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 185
Average Volume 555
Open 5.68
Previous Close 5.82
Day's Range 5.50 - 5.68
52-Week Range 3.80 - 6.90
Beta 0.54
RSI 45.39
Earnings Date Feb 10, 2026

About Read-Gene

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. The chemoprevention segment engages in the use of natural or synthetic substances to inhibit, reverse, or delay the process of cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic oncology consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. It ... [Read more]

Industry Biotechnology & Medical Research
Sector Healthcare
Founded 2005
Employees 20
Stock Exchange Warsaw Stock Exchange
Ticker Symbol RDG
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.